During the past decade, Colorado Blood Cancer Institute conducted 197 clinical trials. In the 10-year time frame, 197 clinical trials started and 102 clinical trials were completed, i.e. on average, 51.8% percent of trials that started reached the finish line to date. In the past 5 years, 80 clinical trials started and 75 clinical trials were completed. i.e. 93.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Colorado Blood Cancer Institute" #1 sponsor was "National Cancer Institute (NCI)" with 68 trials, followed by "SWOG Cancer Research Network" with 28 trials sponsored, "Alliance for Clinical Trials in Oncology" with 22 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 13 trials sponsored and "SCRI Development Innovations, LLC" with 13 trials sponsored. Other sponsors include 132 different institutions and companies that sponsored additional 71 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Colorado Blood Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 85 trials as a collaborator, "NRG Oncology" with 12 trials as a collaborator, "Millennium Pharmaceuticals, Inc." with 8 trials as a collaborator, "Canadian Cancer Trials Group" with 7 trials as a collaborator and "Bristol-Myers Squibb" with 5 trials as a collaborator. Other collaborators include 90 different institutions and companies that were collaborators in the rest 78 trials.

According to Clinical.Site data, the most researched conditions in "Colorado Blood Cancer Institute" are "Multiple Myeloma" (47 trials), "Acute Myeloid Leukemia" (13 trials), "Chronic Lymphocytic Leukemia" (9 trials), "Myelodysplastic Syndrome" (9 trials) and "Recurrent Squamous Cell Lung Carcinoma" (9 trials). Many other conditions were trialed in "Colorado Blood Cancer Institute" in a lesser frequency.

Most popular intervention types in "Colorado Blood Cancer Institute" are "Drug" (224 trials), "Other" (113 trials), "Biological" (99 trials), "Procedure" (47 trials) and "Radiation" (15 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (57 trials), "Quality-of-Life Assessment" (39 trials), "Dexamethasone" (30 trials), "Cyclophosphamide" (26 trials) and "Lenalidomide" (21 trials). Other intervention names were less common.

The vast majority of trials in "Colorado Blood Cancer Institute" are 252 trials for "All" genders, 25 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Colorado Blood Cancer Institute". undefined are not yet recruiting, 70 are recruiting, 100 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 74 completed trials in Colorado Blood Cancer Institute, 4 suspended trials, and 22 terminated clinical trials to date.

Out of the total trials that were conducted in Colorado Blood Cancer Institute, 68 "Phase 1" clinical trials were conducted, 133 "Phase 2" clinical trials and 100 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".